research

The National Science Foundation suspended at least 18 research grants to UC Berkeley last month despite a court injunction restricting such suspensions, according to an attorney representing university scientists in a class-action lawsuit.

The NSF declined to comment on the suspensions.

The grants include at least one that the NSF had previously canceled and was compelled by a federal court order to restore, for a series of mixed-reality exhibits at the Lawrence Hall of Science showcasing Indigenous Ohlone knowledge about the natural world, said one of the project’s leaders, Jedda Foreman.

Foreman, an associate director at the Lawrence Hall of Science, said another researcher on her team received an email from UC Berkeley’s vice chancellor of research, Katherine Yelick, notifying them that the National Science Foundation had suspended the $1.4-million grant. Foreman said she viewed the email, which said the university had received a letter from the NSF raising concerns about “foreign funding.” The email did not provide a copy of the letter or explain further, she said.

Foreman said the Lawrence Hall of Science had not received any foreign funding for the project.

“The grantees were given near-zero information about what was problematic in the execution of their grant,” said Claudia Polsky, a professor at UC Berkeley School of Law who is representing Foreman and other researchers in a suit they filed last year contesting a previous round of grant cancellations by the Trump administration.

Polsky said her legal team was seeking more information about the 18 suspensions, but was concerned that the freezing of Foreman’s grant may violate a court order a federal judge issued in that case restoring the defunded projects.

UC Berkeley spokesperson Dan Mogulof said in a statement that the university “is engaged with the government on matters pertaining to research grants, and remains committed to compliance with all federal laws, rules and regulations.”

He declined to comment on the types of grants affected, the amount of funds at stake, or the potential effect on the campus.

One of the Lawrence Hall of Science exhibits, which were co-designed with Ohlone youth, is scheduled to open Sunday, with another set for the fall of 2028. Researchers also are studying whether participating in creating exhibits sparks more interest in science among Indigenous young people and makes them more likely to pursue STEM careers.

“We’re doing a lot of hoping and finger-crossing that something works out,” Foreman said. “It was such a powerful project and we really want to be able to share what we’ve learned.”

National Science Foundation turmoil

The University of California received $525 million in National Science Foundation grants in the 2024-25 budget year. But that funding source has become increasingly volatile under the Trump administration as the federal agency has terminated nearly 2,000 grants nationwide that it said did not align with its priorities — including those focusing on diversity, equity and inclusion — and has been slower to approve and disburse new awards.

In late April, President Trump fired all 22 members of the independent board of scientists that oversaw the NSF. He is also proposing to cut the agency’s budget by more than half in 2027, though Congress rejected a similar plan last year.

Other federal agencies also terminated research grants en masse last year. Some of the cancellations have been reversed by the courts.

UC researchers are contesting grant reversals by the National Science Foundation, Department of Energy, National Institutes of Health, Department of Transportation, Department of Defense, Environmental Protection Agency and National Endowment for the Humanities in the class-action lawsuit, filed last year. The University of California is not a party to the suit.

Last June, the researchers won a key legal victory when U.S. District Judge Rita Lin issued a preliminary injunction restoring grants canceled by the NSF, EPA and NEH — including for the Ohlone-focused exhibits co-led by Foreman, one of six named plaintiffs in the case. The judge barred the agencies from revoking funds using form letters that didn’t include an explanation specific to the grant at stake, or because of Trump’s anti-DEI executive orders.

Judge Lin stepped in again after the NSF froze hundreds of grants to UCLA in August, amid attempts by the Trump administration to secure a $1-billion settlement from the university over allegations of campus antisemitism. Indefinitely suspending a grant was the same as terminating it, Lin said in a ruling requiring the agency to reinstate the funds.

Polsky said last month’s suspension of Foreman’s grant raised concerns that the Trump administration was seeking a way around those orders. “It seems to us like something that should not have been canceled on the merits and raises suspicion that this was just a different way to cancel the grant,” she said.

UC looks to state for alternative funding

The University of California is ramping up efforts to find alternative funding for its multibillion-dollar research enterprise as federal support becomes less reliable. On Monday, UC President James Milliken spoke alongside state Sen. Scott Wiener and United Auto Workers president Shawn Fain at a Sacramento rally in support of state legislation to create a $23-billion fund for scientific research.

If successful, the bill will place a bond measure on the November ballot. Money from the bond would go toward research in wildfire and pandemic preparedness, new medical treatments and other areas, with revenue from inventions shared with the state. The state Assembly’s appropriations committee is set to consider the bill Thursday.

“If the federal government is going to continue to attempt to reduce funding for the research that has been so important to UC — that saves lives, that drives the economy — then the state of California, I hope, will be able to step up,” Milliken said at a meeting of the university’s Board of Regents on Wednesday.

UC Provost Katherine Newman told the regents she has been meeting with leaders of the Russell Group, a consortium of the United Kingdom’s top universities, to discuss collaborating on research in climate change, clean energy and public health — all areas that have seen federal funding threatened under the current administration.

Mello writes for Berkeleyside, which originally published this story. It was distributed through a partnership with the Associated Press.

WASHINGTON — A former senior adviser to Dr. Anthony Fauci was indicted on federal charges alleging he conspired to hide his communications related to COVID-19 research as the pandemic raged across the country, the Justice Department said Tuesday.

Dr. David Morens, 78, is accused of using his private email account to intentionally circumvent public records laws while employed at the National Institutes of Health. The Justice Department alleges that he concealed or destroyed records of discussions related to COVID-19 research grants, including an effort to revive a controversial coronavirus grant.

“These allegations represent a profound abuse of trust at a time when the American people needed it most — during the height of a global pandemic,” acting Atty. Gen. Todd Blanche said in a statement Tuesday. “Government officials have a solemn duty to provide honest, well-grounded facts and advice in service of the public interest — not to advance their own personal or ideological agendas.”

Morens faces charges of conspiracy against the United States; destruction, alteration or falsification of records in federal investigations; concealment, removal or mutilation of records; and aiding and abetting, according to a Justice Department news release. If convicted, he could face decades in prison. An attorney for Morens declined to comment.

The indictment reflects Republicans’ long-held belief that the federal government covered up key information about COVID-19 as the pandemic unfolded. Despite numerous probes, the origins of COVID have never been proven. Scientists are unsure whether the virus jumped from an animal, as many other viruses have, or came from a laboratory accident. A U.S. intelligence analysis released in 2023 said there is insufficient evidence to prove either theory.

Blanche said Morens’ alleged conduct was part of an effort to “suppress alternative theories” about COVID-19’s origins. The Justice Department also accused Morens of having an improper relationship with a collaborator, including allegedly accepting a gift of wine and discussing COVID-19 research and potential publications in a prominent medical journal.

The indictment follows a probe by House Republicans into the origins of the COVID-19 pandemic that scrutinized Morens’ email communications and accused him of intentionally concealing records. In congressional testimony, Morens denied attempting to evade federal transparency laws by using his personal email.

Gonadorelin, a decapeptide identical in sequence to gonadotropin-releasing hormone, is believed to occupy a foundational position in endocrine signaling research. Since its structural elucidation in the twentieth century, the peptide has served as a conceptual bridge between neurochemical signaling and systemic hormonal coordination within the research model.

Contemporary scientific discourse increasingly frames Gonadorelin not merely as a reproductive regulator, but as a finely tuned molecular signal whose rhythmic release, receptor interactions, and downstream cascades offer insight into broader principles of cellular communication, feedback regulation, and temporal encoding. This article explores Gonadorelin through a research-oriented lens, supporting  its molecular characteristics, signaling properties, hypothesized systemic roles, and emerging investigative domains. The discussion relies on established scientific knowledge while maintaining speculative language appropriate to ongoing inquiry.

Molecular Identity and Structural Considerations

Gonadorelin is a linear decapeptide composed of ten amino acids arranged in a highly conserved sequence across vertebrate species. This conservation has long intrigued researchers, as it suggests evolutionary pressure to preserve both structure and function. From a biochemical perspective, the peptide’s relatively small size belies its extensive signaling reach within the research model.

At the molecular level, Gonadorelin may be viewed as an archetypal neuropeptide, synthesized as part of a larger precursor molecule and subsequently processed into its active form. Its tertiary simplicity allows it to interact with a specific G protein-coupled receptor, commonly referred to as the gonadotropin-releasing hormone receptor. Research indicates that subtle alterations in amino acid composition or terminal modifications may significantly alter receptor affinity, signaling bias, and degradation kinetics. These observations have fueled interest in Gonadorelin analogs as experimental tools for probing receptor dynamics and intracellular signaling selectivity.

Receptor Interaction and Intracellular Signaling Cascades

The interaction between Gonadorelin and its receptor represents a classic model for ligand-receptor specificity in mammalian endocrine research. Upon binding, the receptor undergoes conformational changes that may activate multiple intracellular pathways, including phospholipase C signaling, calcium mobilization, and protein kinase activation. Rather than functioning as a simple on-off switch, Gonadorelin signaling appears to encode information through frequency and amplitude modulation.

Research suggests that pulsatile exposure to Gonadorelin might generate distinct intracellular responses compared to continuous exposure, even when total peptide availability remains constant. This phenomenon has positioned Gonadorelin as a central example in studies of temporal signaling, where timing itself becomes a biologically meaningful variable. Investigations purport that this temporal encoding may influence gene transcription patterns, receptor recycling, and cellular sensitivity over time.

Temporal Dynamics and Rhythmic Signaling

One of the most compelling research properties of Gonadorelin lies in its rhythmic release pattern. Unlike many signaling molecules that operate through steady concentrations, Gonadorelin appears to function optimally through discrete pulses. Scientific inquiry has long theorized that this pulsatility allows the mammalian model to maintain responsiveness while avoiding receptor desensitization.

From a systems biology perspective, Gonadorelin may serve as a model for understanding how oscillatory signals regulate complex physiological networks. Computational analyses and laboratory-based research models have explored how variations in pulse frequency, duration, and interval might translate into differential downstream signaling outcomes. These explorations extend beyond reproductive endocrinology, offering conceptual frameworks potentially relevant to circadian biology, metabolic regulation, and adaptive feedback systems as they prove relevant to mammalian models.

Genetic Regulation and Transcriptional Influence Research

Beyond immediate signaling cascades, Gonadorelin is thought to potentially exert a longer-term interaction with or modulation of gene expression. Research indicates that activation of its receptor may alter transcriptional programs associated with cellular differentiation, hormone synthesis, and receptor expression itself. This layered regulatory architecture suggests that Gonadorelin signaling may participate in both rapid and delayed regulatory loops within the research model.

Epigenetic considerations have also entered the conversation. Some investigations hypothesize that repeated Gonadorelin signaling might influence chromatin accessibility or transcription factor recruitment in target cells. While these concepts remain under active exploration, they underscore the peptide’s potential relevance to developmental biology and long-term cellular adaptation.

Possible Role in Neuroendocrine Integration Research

Gonadorelin seems to occupy a unique intersection between neural signaling and endocrine output. Synthesized within specialized neurons, the peptide appears to translate neural inputs into hormonal coordination. This positioning has encouraged researchers to use Gonadorelin as a proxy for studying neuroendocrine integration more broadly.

Research models have examined how external stimuli such as environmental cues, stress signals, and metabolic states might modulate Gonadorelin synthesis and release. These lines of inquiry suggest that the peptide may function as an integrative node, aligning internal physiological states with external conditions. Such hypotheses elevate Gonadorelin from a single-pathway regulator to a dynamic mediator of cell-wide coherence.

Investigative Implications in Endocrine Research Models

Within laboratory settings, Gonadorelin has been widely referenced as a molecule suited for evaluationg receptor responsiveness, signaling fidelity, and feedback regulation. Its well-characterized sequence and receptor interaction profile make it an ideal benchmark for experimental design. Researchers often employ Gonadorelin to calibrate assays measuring gonadotropin synthesis, second messenger generation, or transcriptional responses.

Beyond traditional endocrine studies, Gonadorelin has found relevance in comparative signaling research. By examining how different cell types respond to identical Gonadorelin stimuli, investigators gain insight into cell-specific signaling architectures and receptor coupling strategies. These approaches may inform broader theories of cellular specialization within multicellular models.

Emerging Hypotheses Beyond Reproductive Signaling

While historically associated with reproductive axis regulation, Gonadorelin has increasingly been discussed in the context of broader biological roles. Some research indicates that its receptor may be expressed in tissues not classically associated with gonadotropin regulation. This observation has led to hypotheses that Gonadorelin signaling might support processes such as cellular proliferation, differentiation, or metabolic coordination in context-dependent ways.

In systems-level analyses, Gonadorelin has been theorized to contribute to network stability by participating in feedback loops that extend beyond a single hormonal axis. These speculative models propose that the peptide’s rhythmic signaling might synchronize multiple physiological subsystems, thereby supporting cellular homeostasis under changing conditions.

Conclusion

Gonadorelin remains one of the most intellectually rich peptides in contemporary biological research. Far from being limited to a narrow endocrine function, the peptide embodies key principles of molecular signaling, temporal regulation, and systems integration within the mammalian model. Its conserved structure, rhythmic signaling properties, and multifaceted intracellular impacts continue to inspire investigation across disciplines ranging from neuroendocrinology to computational biology. Researchers interested in further studying this compound are encouraged to visit Core Peptides.

References

[i] Stamatiades, G. A., & Kaiser, U. B. (2017). Gonadotropin regulation by pulsatile GnRH: Signaling and transcriptional control.Endocrinology, 158(11), 3369–3380.
 https://doi.org/10.1210/en.2017-00425

[ii] Navarro, V. M., & Tena-Sempere, M. (2012). New insights into the control of pulsatile GnRH release.Frontiers in Endocrinology, 3, 48. https://doi.org/10.3389/fendo.2012.00048

[iii] Whitlock, K. E., & Schlarb, J. E. (2019). Is gonadotropin-releasing hormone neurons dispensable for reproductive neuroendocrine function?Journal of Neuroendocrinology, 31(1), e12696. https://doi.org/10.1111/jne.12696

[iv] Flanagan, C. A., & Manilall, J. D. (2017). Gonadotropin-releasing hormone receptors: Structure, ligand binding and intracellular signaling.Frontiers in Endocrinology, 8, 274. https://doi.org/10.3389/fendo.2017.00274

[v] Ohlsson, B. (2016). Gonadotropin-Releasing Hormone and its physiological and pathophysiological roles in relation to the structure and function of the gastrointestinal tract.European Surgical Research, 57(1-2), 22–33. https://doi.org/10.1159/000445717

April 18 (UPI) — President Donald Trump signed an executive order Saturday to accelerate research for some psychedelic drugs to treat mental health disorders.

Surrounded by podcaster Joe Rogan and veterans, the president signed the order that could lead to use of the psychedelics in controlled, therapeutic settings.

“We’re taking this decision, this decisive step, to confront one of the most urgent public health challenges facing our nation, the mental health crisis,” Trump said Saturday in the Oval Office.

“Today’s order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life,” Trump said.

The order directs the Food and Drug Administration to speed its review of new treatments. Trump said the order applies to certain drugs that are already in the “advanced stages of clinical trials.”

Rogan said he sent the president “some information” about the drugs after he heard about them on his podcast, The Hill reported.

“I sent him that information. The text message that came back: ‘Sounds great. Do you want FDA approval? Let’s do it.’ Literally that quick,” Rogan said.

Trump mentioned ibogaine, which has been used to treat post-traumatic stress disorder in other countries. He said the administration would be “opening the pathway” for the drug to be included in the Right to Try Act, which allows terminally ill patients to participate in clinical trials for treatments still under FDA review, The Hill reported. Trump signed that act into law in 2018.

“Under this new program in this administration, drugs can get approved in weeks, not a year or year plus, but in weeks, if they are in line with our national priorities,” FDA Commissioner Martin Makary said at the signing.

“This is an unmet public health need, and there are potentially promising treatments,” Makary said. “That’s why there’s a sense of urgency around this. That’s why we’re doing it now.”

In 2024, 471 U.S. service members died by suicide, and there were 1,515 attempts reported, according to the Pentagon’s Annual Report on Suicide in the Military.

Some of the drugs included are ibogaine; LSD; psilocybin; known as magic mushrooms; and MDMA, known as ecstasy. Trump added that the government had just committed $50 million in additional funding for ibogaine research, The Post reported.

“Federal prohibition of psychedelic medicine in America is over,” said W. Bryan Hubbard, an advocate for access to ibogaine, The Washington Post reported.

Kevin Sabet, who was a White House drug policy adviser over three presidential administrations, disagreed. He said the order will “send the wrong message” and encourages hasty, potentially dangerous research.

“People need to realize there is little to no evidence for most of these drugs and most of the conditions they claim to alleviate,” Sabet, president of Smart Approaches to Marijuana, wrote in a text message to The Post.

Health and Human Services Secretary Robert F. Kennedy Jr. has championed the idea of using psychedelics to help with mental health conditions. On Saturday, he said officials owed it to veterans “to turn over every stone.”

“It’s disturbing to me and to the president that hundreds, in fact, thousands of veterans are having to travel to Mexico or other countries to experiment with interventions that hold great promise,” Kennedy said.